You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Welcome to the 2-Drug Regimen Era

A 20-year-old starting a 3-drug regimen may be on therapy for nearly 6 decades, which translates to more than 60,000 doses of individual medications.  No one should take more medicines than they need.

Read More

Facts on DTG + 3TC

Fast Facts Infographic

Read a summary of DTG + 3TC in
                    this Fast Facts Infographic

Patient Information for DTG + 3TC

Patient Information Booklet

Answers FAQs for patients who have been prescribed DTG + 3TC

*For further details please see the Tivicay and Epivir (lamivudine) SPCs available from

Tivicay + lamivudine is only suitable for the treatment of HIV-1 infection where there is no known or suspected resistance to the integrase inhibitor class, or to lamivudine.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.